|
|
All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, pharmaceutical and sales MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was pharmaceutical repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of sales the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6 Studies indicate that ingested oral cyanocobalamin tablets are ineffective pharmaceutical in the treatment of allergic disease, perhaps because once ingested, they are directly sales metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout pharmaceutical the bloodstream before arriving at the liver. It is during this first pass in its native form that it is believed to exert its therapeutic effect. CLINICAL sales RESEARCH: "The World Health Organization (WHO) recognizes allergic pharmaceutical rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, sales eczema, dermatitis pharmaceutical (contact and atopic)...allergic sales and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 pharmaceutical In 1988, sales asthma and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE pharmaceutical and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. sales Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites pharmaceutical in Riverside County, CA in 1989. Sixteen of the 17 subjects sales had lowered IgE levels from Day 0 to Day 30.3
|